Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection) has been made available by Endo for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBA) after surgery, while decreasing the peripheral muscarinic effects (eg, bradycardia and excessive secretions) associated with cholinesterase inhibition following NMBA reversal administration.
Prevduo contains a fixed-dose combination of neostigmine, a cholinesterase inhibitor and glycopyrrolate, an antimuscarinic agent. Both drugs have been previously approved as single agent products; the new combination removes the need for 2 syringe preparations and administrations.
“This is the latest way we’re addressing operational and clinical challenges in order to support patient care,” said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. “With 2 medications in one ready-to-use syringe, Prevduo reduces complexity and increases efficiency for hospitals and health care providers.”
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.